The world's first chimeric monkeys were created in a laboratory last year, and they offer surprising new insights
into embryonic stem cell therapy: One reason for often - poor treatment outcomes may be that we're using embryos that are, strangely, just too old.
Not exact matches
The immediate payoff was a commercialization deal in age - related macular degeneration in which Pfizer became the first big pharma company to make a move
into the use of
embryonic stem cells as the basis for a tissue regeneration
therapy.
The finding could fundamentally change how we look at human
stem cell tech: If chimeric monkeys require totipotent
cells before they can come
into being, it stands to reason that human
embryonic stem cell therapy might also require totipotent
stem cells to render cures.
A fix for broken rat hearts Scientists this week successfully implanted human
embryonic stem cells into rats that suffered heart attacks, coming a heartbeat closer to realizing the full potential of such
therapy.
This information could then be used to prompt
embryonic stem cells to differentiate in the culture dish
into neurons for potential use in
cell - replacement
therapy.
This approach to derive patient - specific
Embryonic Stem cell - like
cells (iPS
cells) is going to open up research
into the genetic causes of disease and the search for
therapies not only for such diseases, but also for repairing tissues damaged in other ways.
Lanza's dream of turning human
embryonic stem cells into therapies for the sick and the suffering is taking a huge step closer to reality.